Schräder R, Degoutrie G, Landgraf H, Kaltenbach M
Klin Wochenschr. 1987 Jan 15;65(2):69-75. doi: 10.1007/BF01745476.
A hyperkinetic heart syndrome has been diagnosed in 10 patients by clinical investigation and right-heart catheterization at rest and during exercise. Subsequently, the patients received 3 X 40 mg alinidine, and 2 X 40 mg propranolol and placebo, each for 2 weeks in a double-blind crossover study. Heart rate at rest (P less than 0.05) and during exercise (P less than 0.001) decreased significantly under alinidine and propranolol to the same extent (control, 83/170; alinidine, 68/146; propranolol, 73/139; placebo, 83/162 beats per min). Lower limb flow at rest and after exercise, measured by plethysmography, as well as left-ventricular fractional shortening and mean velocity of circumferential fiber shortening, measured by echocardiography, decreased insignificantly. Sedation and a dry mouth occurred in six patients under alinidine, while fatigue and cold hands and/or feet were reported by five patients under propranolol. Thus, alinidine may be used as an alternative to beta-blocking in the treatment of the hyperkinetic heart syndrome.
通过临床检查以及静息和运动状态下的右心导管插入术,已确诊10例患者患有运动亢进性心脏综合征。随后,在一项双盲交叉研究中,这些患者分别接受了3次每次40毫克的烯丙尼定、2次每次40毫克的普萘洛尔和安慰剂治疗,每种药物治疗2周。在烯丙尼定和普萘洛尔治疗下,静息心率(P<0.05)和运动心率(P<0.001)均显著下降,且下降程度相同(对照组,83/170;烯丙尼定组,68/146;普萘洛尔组,73/139;安慰剂组,83/162次/分钟)。通过体积描记法测量的静息和运动后下肢血流量,以及通过超声心动图测量的左心室缩短分数和圆周纤维缩短平均速度,下降不显著。6例接受烯丙尼定治疗的患者出现镇静和口干,而5例接受普萘洛尔治疗的患者报告有疲劳和手脚冰凉。因此,在运动亢进性心脏综合征的治疗中,烯丙尼定可作为β受体阻滞剂的替代药物。